Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Convertible Debt (2016 - 2020)

Zevra Therapeutics' Convertible Debt history spans 6 years, with the latest figure at $67.7 million for Q4 2020.

  • For Q4 2020, Convertible Debt fell 12.52% year-over-year to $67.7 million; the TTM value through Dec 2020 reached $67.7 million, down 12.52%, while the annual FY2020 figure was $67.7 million, 12.52% down from the prior year.
  • Convertible Debt reached $67.7 million in Q4 2020 per ZVRA's latest filing, down from $77.3 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $90.8 million in Q3 2016 to a low of $67.7 million in Q4 2020.
  • Average Convertible Debt over 4 years is $81.6 million, with a median of $82.5 million recorded in 2018.
  • Peak YoY movement for Convertible Debt: surged 1118.53% in 2016, then fell 19.06% in 2019.
  • A 4-year view of Convertible Debt shows it stood at $90.8 million in 2016, then fell by 13.96% to $78.1 million in 2018, then decreased by 0.98% to $77.3 million in 2019, then decreased by 12.52% to $67.7 million in 2020.
  • Per Business Quant, the three most recent readings for ZVRA's Convertible Debt are $67.7 million (Q4 2020), $77.3 million (Q4 2019), and $70.6 million (Q3 2019).